BioWorld MedTech

Oct. 4, 2018

V-Wave kicks off enrollment in pivotal study of device for HF

Israeli startup V-Wave Ltd. reported the start of enrollment in a study of a minimally invasive device to treat patients with New York Heart Association (NYHA) class III and ambulatory class IV symptomatic heart failure (HF). Read More

Lungvision launch seen as step towards winning battle against lung cancer

Neovasc heads for U.S. with Reducer, a minimally invasive angina implant

Datascope warning letter cites supplier, design verification issues

Do drug, device companies meet California's boardroom quota of women?

Appointments and advancements

Daily M&A

Financings

Regulatory front

Product briefs

Other news to note

BioWorld MedTech's Orthopedics Extra

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 17, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

European Commission floats multiple fixes for MDR, IVDR

BioWorld MedTech

The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...

Apollo’s APL-4098 shows potent antileukemic effects

BioWorld Science

Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.